Article
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2023
Geng Chuandong, Zhang Man-Chao, Manyam Ganiraju C, Vykoukal Jody V, Fahrmann Johannes F, Peng Shan, Wu Cheng, Park Sanghee, Kondraganti Shakuntala, Wang Daoqi, Robinson Brian D, Loda Massimo, Barbieri Christopher E, Yap Timothy A, Corn Paul G, Hanash Samir, Broom Bradley M, Pilié Patrick G, Thompson Timothy C
Abstract excerpt
PURPOSE: Speckle-type POZ protein (SPOP) is important in DNA damage response (DDR) and maintenance of genomic stability. Somatic heterozygous missense mutations in the SPOP substrate-binding cleft are found in up to 15% of prostate cancers. While mutations in SPOP predict for benefit from androgen receptor signaling inhibition (ARSi) therapy, outcomes for patients with SPOP-mutant (SPOPmut) prostate cancer are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
